Found: 3
Select item for more details and to access through your institution.
Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.
- Published in:
- British Journal of Haematology, 2010, v. 150, n. 3, p. 293, doi. 10.1111/j.1365-2141.2010.08235.x
- By:
- Publication type:
- Article
Promoter hypermethylation of p15<sup> INK4 B</sup>, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients.
- Published in:
- European Journal of Haematology, 2006, v. 76, n. 1, p. 23, doi. 10.1111/j.1600-0609.2005.00559.x
- By:
- Publication type:
- Article
Validation of the revised international prognostic scoring system ( IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS ( EUMDS) registry.
- Published in:
- British Journal of Haematology, 2015, v. 170, n. 3, p. 372, doi. 10.1111/bjh.13450
- By:
- Publication type:
- Article